Novo Nordisk A/S – Share repurchase programme
November 05 2021 - 4:55PM
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark,
5 November
2021 — As part of the up to DKK
20.0 billion 2021 share repurchase programme, Novo Nordisk A/S has
now initiated a new share repurchase programme for an amount of up
to DKK 3.7 billion in accordance with Article 5 of Regulation No
596/2014 of the European Parliament and Council of 16 April 2014
(MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8
March 2016 (the "Safe Harbour Rules”).
For that purpose, Novo Nordisk A/S has appointed Skandinaviska
Enskilda Banken, Danmark, filial af Skandinaviska Enskilda Banken
AB, as lead manager to execute the programme independently and
without influence from Novo Nordisk A/S. The purpose of the
programme is to reduce the company’s share capital and to meet
obligations arising from share-based incentive programmes. Under
the agreement, Skandinaviska Enskilda Banken, Danmark, filial af
Skandinaviska Enskilda Banken AB, will repurchase B shares on
behalf of Novo Nordisk A/S during the trading period starting 8
November 2021 and ending on 1 February 2022. No repurchase will
take place during the period 22 December to 31 December 2021 (both
days inclusive).
A maximum of 190,000,000 B shares in total can be bought during
the trading period. The maximum number of B shares that can be
repurchased on a single trading day may not exceed 20% of the
average daily trading volume of Novo Nordisk B shares on the
trading venue, on which the purchase takes place, in the preceding
20 trading days of the purchase (excluding the day of the
purchase). At least once every seven trading days, Novo Nordisk A/S
will issue an announcement in respect of the transactions made
under the share repurchase programme.About Novo Nordisk
A/SNovo Nordisk is a leading global healthcare company,
founded in 1923 and headquartered in Denmark. Our purpose is to
drive change to defeat diabetes and other serious chronic diseases
such as obesity and rare blood and endocrine disorders. We do so by
pioneering scientific breakthroughs, expanding access to our
medicines, and working to prevent and ultimately cure disease. Novo
Nordisk employs about 47,000 people in 80 countries and markets its
products in around 170 countries. Novo Nordisk's B shares are
listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the
New York Stock Exchange (NVO). For more information, visit
novonordisk.com, Facebook, Twitter, LinkedIn, and YouTube.
Further information
Media: |
|
|
Mette Kruse
Danielsen |
+45 3079 3883 |
mkd@novonordisk.com |
Michael Bachner
(US) |
+1 609 664
7308 |
mzyb@novonordisk.com |
|
|
|
Investors: |
|
|
Daniel Muusmann
Bohsen |
+45 3075 2175 |
dabo@novonordisk.com |
Ann Søndermølle
Rendbæk |
+45 3075 2253 |
arnd@novonordisk.com |
David Heiberg
Landsted |
+45 3077 6915 |
dhel@novonordisk.com |
Mark Joseph Root
(US) |
+1 848 213
3219 |
mjhr@novonordisk.com |
- CA20211105 - Share repurchase
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jul 2023 to Jul 2024